Dr. Davids on the Use of CAR T-Cell Therapy in CLL

Video

Matthew S. Davids, MD, MMSc, associate director, Center for Lymphocytic Leukemia, physician, Dana-Farber Cancer Institute, and assistant professor of medicine, Harvard Medical School, discusses the use of CAR T-cell therapy for the treatment of patients with chronic lymphocytic leukemia (CLL).

Matthew S. Davids, MD, MMSc, associate director, Center for Lymphocytic Leukemia, physician, Dana-Farber Cancer Institute, and assistant professor of medicine, Harvard Medical School, discusses the use of CAR T-cell therapy for the treatment of patients with chronic lymphocytic leukemia (CLL).

Currently, patients with high-risk CLL have short survival with novel agent monotherapy. A recent study using lisocabtagene maraleucel (liso-cel; JCAR017) for patients with CLL showed a promising complete remission rate of 45.5%. Additionally, 60% of patients had undetectable minimal residual disease by next-generation sequencing at day 30, and 27% of patients showed a deepened response after day 30.

Investigators are waiting to see how patients react long-term after receiving liso-cel, but the results look promising. The safety profile is favorable in these patients who have already been exposed to ibrutinib (Imbruvica) and venetoclax (Venclexta). According to Davids, more research needs to be conducted to see the effects of liso-cel alone and in combination with ibrutinib.

Related Videos
Akshay Sharma, MBBS, a bone marrow transplant physician at St. Jude Children’s Research Hospital
M. Peter Marinkovich, MD, on Bringing RDEB Treatment to the Local Level
Caspian Oliai, MD, MS, the medical director of the UCLA Bone Marrow Transplantation Stem Cell Processing Center
Frederick “Eric” Arnold, PhD
Genovefa (Zenia) Papanicolaou, MD, an infectious diseases specialist at Memorial Sloan Kettering Cancer Center
Jeffrey Chamberlain, PhD, on Exciting New Research at MDA 2024
Alan Beggs, PhD, on Challenges in Therapeutic Development for Rare Diseases
Akshay Sharma, MBBS, a bone marrow transplant physician at St. Jude Children’s Research Hospital
PJ Brooks, PhD
John DiPersio, MD, PhD, the director of the Center for Gene and Cellular Immunotherapy at Washington University School of Medicine
© 2024 MJH Life Sciences

All rights reserved.